Treatment of itch in dogs: a mechanistic approach

Olivry, Thierry; Baeumer, Wolfgang

doi:10.1002/9781119278368.ch3.3

Cited by 4 publications

(9 citation statements)

References 68 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…It is also recognized that dogs with CM/SM can excessively rub or scratch their heads or ears and that this is not necessarily associated with SM and is not phantom scratching . The association of SM to scratching has led to the misconception that it causes generalized pruritus, and consequently investigation and treatment of skin disease could be missed …”

Section: Introductionmentioning

confidence: 99%

Behavioral and clinical signs of Chiari‐like malformation‐associated pain and syringomyelia in Cavalier King Charles spaniels

Rusbridge

McFadyen²,

Knower

2019

Veterinary Internal Medicne

View full text Add to dashboard Cite

Background Diagnosis of Chiari‐like malformation‐associated pain (CM‐P) or clinically relevant syringomyelia (SM) is challenging. We sought to determine common signs. Animals One hundred thirty client‐owned Cavalier King Charles spaniels with neuroaxis magnetic resonance imaging (MRI) and diagnosis of CM‐P/SM. Dogs with comorbidities causing similar signs were excluded with exception of otitis media with effusion (OME). Methods Retrospective study of medical records relating signalment, signs, and MRI findings. Dogs were grouped by SM maximum transverse diameter (1 = no SM; 2 = 0.5‐1.99 mm; 3 = 2‐3.9 mm: 4 = ≥4 mm). Differences between all groups—groups 1 versus 2‐4 and groups 1‐3 versus 4—were investigated. Continuous variables were analyzed using 2‐sample t‐tests and analysis of variance. Associations between categorical variables were analyzed using Fisher's exact or chi‐square tests. Results Common signs were vocalization (65.4%), spinal pain (54.6%), reduced activity (37.7%), reduced stairs/jumping ability (35.4%), touch aversion (30.0%), altered emotional state (28.5%), and sleep disturbance (22%). Head scratching/rubbing (28.5%) was inversely associated with syrinx size (P = .005), less common in group 4 (P = .003), and not associated with OME (P = .977). Phantom scratching, scoliosis, weakness, and postural deficits were only seen in group 4 (SM ≥4 mm; P = .004). Conclusions and Clinical Importance Signs of pain are common in CM/SM but are not SM‐dependent, suggesting (not proving) CM‐P causality. Wide (≥4 mm) SM is associated with signs of myelopathy and, if the dorsal horn is involved, phantom scratching (ipsilateral) and torticollis (shoulder deviated ipsilateral; head tilt contralateral).

show abstract

Section: Introductionmentioning

confidence: 99%

Behavioral and clinical signs of Chiari‐like malformation‐associated pain and syringomyelia in Cavalier King Charles spaniels

Rusbridge

McFadyen²,

Knower

2019

Veterinary Internal Medicne

View full text Add to dashboard Cite

show abstract

“…7 Basit klinik tanımlama ile akut (henüz yeni beliren kaşınma duyusunun oluştuğu alanda şekillenerek, kısa müddette pruritik davranış ile bastırılabilir) ve kronik (ortaya çıkışında birbirinden çok farklı etiyolojik nedenler mevcuttur) olabilmektedir. [8][9][10] Buraya kadar genel bilgiler özetinde verilen kaşıntının özelinde, veteriner hekimliği alanına yönelik bir derleme makalesi mevcuttur. 10 Bu çalışmada, mekanik yaklaşım ile köpeklerde kaşıntının derinine irdelenmesi amaçlanmıştır.…”

unclassified

“…[8][9][10] Buraya kadar genel bilgiler özetinde verilen kaşıntının özelinde, veteriner hekimliği alanına yönelik bir derleme makalesi mevcuttur. 10 Bu çalışmada, mekanik yaklaşım ile köpeklerde kaşıntının derinine irdelenmesi amaçlanmıştır. 10 Kaşıntının bu ilginç ve anatomik ya da moleküler şekline rağmen, alerjik dermatit ya da atopi ve benzeri hastalıklarla ilişkisi öteden beri iyi bilinmektedir.…”

unclassified

“…10 Bu çalışmada, mekanik yaklaşım ile köpeklerde kaşıntının derinine irdelenmesi amaçlanmıştır. 10 Kaşıntının bu ilginç ve anatomik ya da moleküler şekline rağmen, alerjik dermatit ya da atopi ve benzeri hastalıklarla ilişkisi öteden beri iyi bilinmektedir. Kliniklere getirilen köpeklerin %20'sinde kaşıntı ile karşılaşılmaktadır.…”

unclassified

“…Köpeklerde kaşıntı dermatolojik, sistemik, nörolojik, psikolojik, çeşitli hastalıkların bir arada bulunması ve diğer sebeplerden kaynaklı çeşitli etiyolojilere bağlı oluşmaktadır (Tablo 1). 10 Bu çalışmada, kaşıntısı olan köpeklerde doğal peptid analoğu laktoferrisin B'nin alerjik dermatitli köpeklerde antipuritik amaçla kullanımı ile etkinliğinin saptanması amaçlanmıştır. Çalışmaya katılması planlanan köpekler (hasta sahibi bilgi onam formu ve gönüllülük esasına dayalı olarak) a) Willemse'nin kriterlerine uygunluk, b) Benzer hastalık tablosuna neden olabilecek paraziter dermatozlar ya da primer bakteriyel enfeksiyon gibi tüm nedenler ekarte edildikten sonra, c) Atopinin dışlanması (CADESI-03 skorlaması, Favrot kriterleri), d) Altı haftanın üzerinde gıda eliminasyon diyeti (hasta sahibinin tercihine göre evde pişen gıdalar ya da alternatif olarak ticari hipoallerjenik diyet) yönünden değerlendirmeye tabi tutulmuştur.…”

unclassified

See 2 more Smart Citations

The Use of Natural Peptide Analogue Lactoferrin B for Antipruritic Purposes in Pruritic Dogs and its Effects on pH with Epidermal Hydration

Ural¹,

Yağci²,

Erdoğan³

et al. 2019

Turkiye Klinikleri J Vet Sci

View full text Add to dashboard Cite

show abstract

Efficacy and safety of 0.0584% hydrocortisone aceponate topical spray and systemic oclacitinib combination therapy in dogs with atopic dermatitis: a randomized, double‐blinded, placebo‐controlled trial

Takahashi¹,

Kanda²,

Imanishi

et al. 2020

Veterinary Dermatology

View full text Add to dashboard Cite

Background Oclacitinib is an effective systemic therapy for dogs with atopic dermatitis (AD). Few studies have evaluated concurrent topical treatment with oclacitinib in dogs. Objectives To evaluate the efficacy and safety of combination therapy of oclacitinib and 0.0584% hydrocortisone aceponate (HCA) spray in dogs with AD. Animals Eighteen dogs with AD. Methods and materials This study was a randomized, double‐blinded, placebo‐controlled trial. All dogs were treated with oclacitinib (0.4–0.6 mg/kg twice daily for 14 days, then once daily for 14 days) and randomized to receive either HCA spray or placebo spray, applied once daily for seven days then every other day through to Day (D)28. Clinical assessments included the Canine Atopic Dermatitis Extent and Severity Index, 4th iteration (CADESI‐4) and the pruritus Visual Analog Scale (PVAS) every seven days, and blood and urine tests every 14 days. Results The mean CADESI‐4 and PVAS scores were significantly reduced on D7 and D14 compared to D0 in both groups (P < 0.05). From D14 to D21, CADESI‐4 and PVAS scores were significantly increased in the placebo group (P < 0.005), and not in the HCA‐treated group. The mean reduction from baseline of the HCA‐treated group was significantly higher than that of the placebo group for the PVAS and CADESI‐4 on D21 (59.9% versus 27.6%, P = 0.0216) and D28 (56.0% versus 30.5%, P = 0.0109), respectively. One dog in the HCA‐treated group was withdrawn as a consequence of developing diarrhoea. Conclusion Topical application of 0.0584% HCA spray may be useful for preventing exacerbation of pruritus and clinical lesions when tapering oclacitinib therapy in dogs with AD.

show abstract

Treatment of itch in dogs: a mechanistic approach

Cited by 4 publications

References 68 publications

Behavioral and clinical signs of Chiari‐like malformation‐associated pain and syringomyelia in Cavalier King Charles spaniels

Behavioral and clinical signs of Chiari‐like malformation‐associated pain and syringomyelia in Cavalier King Charles spaniels

The Use of Natural Peptide Analogue Lactoferrin B for Antipruritic Purposes in Pruritic Dogs and its Effects on pH with Epidermal Hydration

Efficacy and safety of 0.0584% hydrocortisone aceponate topical spray and systemic oclacitinib combination therapy in dogs with atopic dermatitis: a randomized, double‐blinded, placebo‐controlled trial

Contact Info

Product

Resources

About